Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Histone deacetylase 2 (HDAC2) is a chromatin modifier implicated in epigenetic regulation.
• HDAC2 is frequently upregulated in human hepatocellular carcinoma (HCC), suggesting its role in cancer progression.

Purpose of the Study:

• To investigate the therapeutic potential of targeting HDAC2 in HCC.
• To determine the effects of HDAC2 inhibition on HCC cell growth, apoptosis, and key signaling pathways.

Main Methods:

• Utilized siRNA-mediated silencing of HDAC2 in HCC cell lines.
• Analyzed changes in cell cycle progression, apoptosis markers, and gene expression.
• Investigated the impact on signaling pathways regulating metabolism (lipogenesis and glycolysis).
• Evaluated systemic delivery of HDAC2 siRNA encapsulated in lipid nanoparticles in a murine xenograft model.

Main Results:

• HDAC2 silencing inhibited HCC cell proliferation by arresting cell cycle and inducing apoptosis.
• Deregulation of key genes involved in cell cycle (p27, acetylated p53, CDK6, BCL2) and lipid metabolism was observed.
• HDAC2 inhibition suppressed PPARγ signaling, glycolysis (ChREBPα, GLUT4), and lipogenesis (SREBP1C, FAS), reducing fat accumulation.
• Systemic administration of HDAC2 siRNA effectively blunted human HCC growth in vivo.

Conclusions:

• Specific targeting of HDAC2 is sufficient to inhibit HCC progression.
• HDAC2 blockade represents a promising preclinical strategy for systemic therapy in liver cancer.